Literature DB >> 26741855

Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.

William T Jorgensen1, Damien W Gulliver2, Eryn L Werry3, Tristan Reekie1, Mark Connor4, Michael Kassiou5.   

Abstract

A previously identified, non-peptidic oxytocin (OT) receptor agonist WAY-267,464 (1) and nine novel derivatives (3, 4a-7a, 4b-7b) were synthesised and evaluated in vitro with the aim of systematically exploring hydrogen bonding interactions and ligand flexibility. All analogues were subjected to competition radioligand binding assays at human oxytocin (OT) and arginine vasopressin 1a (V1a) receptors. Physiological activity was determined using whole cell IP1 accumulation assays. Under these conditions, WAY-267,464 had higher affinity for the V1a receptor compared to the OT receptor (8.5x more selective) with poor functional selectivity (2x selective for OT receptor agonism over V1a receptor antagonism). Methylation of the resorcinol moiety (3) reversed the OT receptor pharmacological profile, removing agonist activity and inducing antagonist activity, without altering V1a receptor pharmacology. All flexible tethered derivatives removed OT receptor affinity and activity resulting in the generation of highly selective V1a receptor ligands.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Arginine vasopressin 1(a) receptor; Diazepine; Oxytocin receptor; WAY-267,464

Mesh:

Substances:

Year:  2015        PMID: 26741855     DOI: 10.1016/j.ejmech.2015.11.050

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Employing the Operational Model to Measure System-Independent OTR Efficacy.

Authors:  Kiyan Afzali; Mark Connor
Journal:  Methods Mol Biol       Date:  2022

2.  The Current Status of Drug Discovery for the Oxytocin Receptor.

Authors:  Philippe E Nashar; Aidan A Whitfield; Jiri Mikusek; Tristan A Reekie
Journal:  Methods Mol Biol       Date:  2022
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.